What was studied?
A subgroup analysis used an existing blinded trial to examine people with HIV receiving integrase-inhibitor-based treatment.
What did the researchers report?
Among the reported participants, tesamorelin reduced visceral and hepatic fat measurements relative to placebo, with comparable reported adverse-event frequencies.
What are the limits?
The subgroup was small and derived from a parent study. It is not an independent replication or evidence for effects in people without HIV.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.